Skip to main content
Top
Published in: Current Gastroenterology Reports 10/2023

17-10-2023 | Sarcopenia

Nutrition in Liver Disease – A Review

Authors: Corrin Hepburn, Natasha von Roenn

Published in: Current Gastroenterology Reports | Issue 10/2023

Login to get access

Abstract

Purpose of Review 

Nutrition is commonly overlooked in chronic liver disease. Both obesity and malnutrition are independent risk factors of poor prognosis in cirrhosis. This review aims to summarize the current literature regarding how nutrition contributes to liver disease, how to screen patients, and what nutritional and activity recommendations can help prevent adverse outcomes.

Recent Findings

Screening for malnutrition, obesity, and sarcopenia through ambulatory bedside methods is recommended every 8–12 weeks in high risk patients. A Mediterranean diet with emphasis on high protein intake of 1.2–1.5 g/kg/day, and increasing physical activity can help to improve nutritional status.

Summary

It remains critical to screen and identify patients with liver disease for malnutrition, obesity, and sarcopenia. Identifying an individualized action plan through a multidisciplinary approach can be helpful. Dietary recommendations to improve outcomes should be based on well-studied approaches. These can include the use of the Mediterranean diet in those with metabolic dysfunction-associated steatotic liver disease (MASLD) and a high protein diet in those with cirrhosis and sarcopenia. Routine assessment of improvement or decline should continue throughout a patient's clinical course.
Appendix
Available only for authorised users
Literature
9.
go back to reference NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2003/. Accessed 15 May 2023. NHLBI Obesity Education Initiative Expert Panel on the Identification, Evaluation, and Treatment of Obesity in Adults (US). Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda (MD): National Heart, Lung, and Blood Institute; 1998. Available from: https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK2003/​. Accessed 15 May 2023.
16.
go back to reference Loomba R. Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J Sanyal, Jörn M Schattenberg, Philip N Newsome; Semaglutide 2–4mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gatsroenterol Hepatol. 2023;8(6):511–22.CrossRef Loomba R. Manal F Abdelmalek, Matthew J Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J Sanyal, Jörn M Schattenberg, Philip N Newsome; Semaglutide 2–4mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gatsroenterol Hepatol. 2023;8(6):511–22.CrossRef
17.
go back to reference Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison; A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24. https://doi.org/10.1056/NEJMoa2028395.CrossRef Philip N. Newsome, Kristine Buchholtz, Kenneth Cusi, Martin Linder, Takeshi Okanoue, Vlad Ratziu, Arun J Sanyal, Anne-Sophie Sejling, Stephen A Harrison; A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113–24. https://​doi.​org/​10.​1056/​NEJMoa2028395.CrossRef
21.
go back to reference Wu Y, Zhu Y, Feng Y, Wang R, Yao N, Zhang M, Liu X, Liu H, Shi L, Zhu L, Yang N, Chen H, Liu J, Zhao Y, Yang Y. Royal Free Hospital-Nutritional Prioritizing Tool Improves the Prediction of Malnutrition Risk Outcomes in Liver Cirrhosis Patients Compared with Nutritional Risk Screening 2002. Br J Nutr, U.S. National Library of Medicine, https://pubmed.ncbi.nlm.nih.gov/32600494/. Accessed 18 May 2023. Wu Y, Zhu Y, Feng Y, Wang R, Yao N, Zhang M, Liu X, Liu H, Shi L, Zhu L, Yang N, Chen H, Liu J, Zhao Y, Yang Y. Royal Free Hospital-Nutritional Prioritizing Tool Improves the Prediction of Malnutrition Risk Outcomes in Liver Cirrhosis Patients Compared with Nutritional Risk Screening 2002. Br J Nutr, U.S. National Library of Medicine, https://​pubmed.​ncbi.​nlm.​nih.​gov/​32600494/​. Accessed 18 May 2023.
22.
go back to reference Borhofen SM, Gerner C, Lehmann J, Fimmers R, Görtzen J, Hey B, Geiser F, Strassburg CP, Trebicka J. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. Dig Dis Sci, U.S. National Library of Medicine, https://pubmed.ncbi.nlm.nih.gov/26725059/. Accessed 18 May 2023. Borhofen SM, Gerner C, Lehmann J, Fimmers R, Görtzen J, Hey B, Geiser F, Strassburg CP, Trebicka J. The Royal Free Hospital-Nutritional Prioritizing Tool Is an Independent Predictor of Deterioration of Liver Function and Survival in Cirrhosis. Dig Dis Sci, U.S. National Library of Medicine, https://​pubmed.​ncbi.​nlm.​nih.​gov/​26725059/​. Accessed 18 May 2023.
26.
go back to reference • Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611–44. https://doi.org/10.1002/hep.32049. Guideline statements developed by a panel of experts from AASLD on liver disease, specifically cirrhosis and malnutrition, frailty, and sarcopenia published in 2021. • Lai JC, Tandon P, Bernal W, Tapper EB, Ekong U, Dasarathy S, Carey EJ. Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(3):1611–44. https://​doi.​org/​10.​1002/​hep.​32049. Guideline statements developed by a panel of experts from AASLD on liver disease, specifically cirrhosis and malnutrition, frailty, and sarcopenia published in 2021.
Metadata
Title
Nutrition in Liver Disease – A Review
Authors
Corrin Hepburn
Natasha von Roenn
Publication date
17-10-2023
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 10/2023
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-023-00887-4

Other articles of this Issue 10/2023

Current Gastroenterology Reports 10/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.